ORPHA:2942
Postpoliomyelitis syndrome
Also known as: Postpolio syndrome · Postpoliomyelitic syndrome
Publications
2,005
Trials
20
Interventional, condition-specific
Researchers
813
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Postpoliomyelitis syndrome (PPS) is a neurologic disorder characterized by the development of new neuromuscular symptoms such as muscular weakness or abnormal muscle fatigability occurring in survivors of the acute paralytic form of poliomyelitis, 15-40 years after recovery from the disease, and that is unexplained by other medical causes. Other manifestations that can occur gradually include generalized fatigue, muscle atrophy, muscle and joint pain, intolerance to cold, and difficulties sleeping, swallowing or breathing.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0017416
- MeSH:D016262
- UMLS:C0080040
Additional Mondo synonyms (6)
Post Polio Syndrome · postpolio sequelae · postpolio syndrome · postpoliomyelitic syndrome · postpoliomyelitis sequelae · postpoliomyelitis syndrome
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
2,005 matched papers (734 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
20 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
2,005
2,005 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
2,005 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
734 in the last 10 years · low confidence
Phrase hits: 2,005 · MeSH hits: 0
Who's working on it?
813
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Nollet F12 papers · 2026
Amsterdam UMC location University of Amsterdam, Department of Rehabilitation Medicine; Amsterdam Movement Sciences, Rehabilitation & Development, Amsterdam, The Netherlands.
Papers in Europe PMC - 02Koopman FS8 papers · 2026
University of Amsterdam, Amsterdam, The Netherlands s.koopman@amc.uva.nl.
Papers in Europe PMC - 03Borg K7 papers · 2024
Division of Rehabilitation Medicine, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.
Papers in Europe PMC - 04Voorn EL7 papers · 2026
Amsterdam UMC location University of Amsterdam, Department of Rehabilitation Medicine; Amsterdam Movement Sciences, Rehabilitation & Development, Amsterdam, The Netherlands. e.l.voorn@amsterdamumc.nl.
Papers in Europe PMC - 05Beelen A6 papers · 2018
Department of Rehabilitation, AMC, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands. Electronic address: j.a.beelen@amc.nl.
Papers in Europe PMC - 06Oliveira ASB6 papers · 2024
Neuromuscular Disorders Unit, Department of Neurology, Universidade Federal de São Paulo, São Paulo, Brazil.
Papers in Europe PMC - 07
- 08
- 09Oorschot S5 papers · 2026
Amsterdam UMC location University of Amsterdam, Department of Rehabilitation Medicine; Amsterdam Movement Sciences, Rehabilitation & Development, Amsterdam, The Netherlands.
Papers in Europe PMC - 10
Clinical research
Is a treatment being tested?
20
interventional trials for this specific condition
20 interventional trials matched this specific condition name; 2 currently recruiting in our sample.
Data as of 27 July 2026
20 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 94.5th percentile).
low confidence · 94.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
20 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07478172·RECRUITING·Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Conditions: Neuromuscular Diseases (NMD) · Amyotrophic Lateral Sclerosis · Myasthenia Gravis · Lambert-eaton Myasthenic Syndrome·Matched via name phrase
- NCT05644522·RECRUITING·Nomad P-KAFO Study
Conditions: Cerebrovascular Accident · Post-polio Syndrome · Spinal Cord Injuries · Multiple Sclerosis·Matched via name phrase
Observational and natural-history studies
5 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT05663008·RECRUITING·Impairments of Neuro-muscular Communication in Motor-Neuron Disease: A Bio-Marker for Early and Personalised Diagnosis
Conditions: ALS (Amyotrophic Lateral Sclerosis) · Postpoliomyelitis Syndrome · Spinal Muscular Atrophy·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Postpoliomyelitis syndrome" OR "Postpolio syndrome" OR "Postpoliomyelitic syndrome" OR "Post Polio Syndrome" OR "postpolio sequelae" OR "postpoliomyelitis sequelae"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Postpoliomyelitis syndrome" OR "Postpolio syndrome" OR "Postpoliomyelitic syndrome" OR "Post Polio Syndrome" OR "postpolio sequelae" OR "postpoliomyelitis sequelae"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 20 interventional · 5 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (2005) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T21:44:56.434Z